Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Waters and Genovis Enter Biopharmaceutical Partnership | Contract Pharma

What are you searching for?

Sign in
Breaking News

Waters and Genovis Enter Biopharmaceutical Partnership

Collaboration intended to bring speed and simplicity to bio-characterization workflows.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Waters Corporation and Genovis AB are collaborating to develop and market complete routine biopharmaceutical characterization workflows based on the Waters BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. The goal of the collaboration is to develop automated workflows for the rapid and consistent characterization of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs in bioprocess development, formulation, stability testing and quality control (QC).
 
“Biologics analysis is an area that is ripe for improvement. What takes analytical scientists several days to do, should take hours or minutes instead,” said Jeff Mazzeo, vice president, global marketing and scientific operations, Waters Corporation. “Today, up-front sample preparation is a major bottleneck to productivity, largely due to the number of manual steps involved and the outmoded technology by which samples are readied for analysis. By combining Genovis’ SmartEnzymes with automation, liquid chromatography/time-of-flight mass spectrometry and application-specific software workflows from Waters, we intend to move biotherapeutic analysis forward in ways never thought possible.”
 
Fredrik Olsson, CEO, Genovis AB, said, “The BioAccord LC-MS system and the Andrew+ pipetting robot align perfectly with our strategies and vision at Genovis to bring simplified, robust and automated enzyme-driven workflows to the biopharma industry. The enzymatic workflows that we will develop in collaboration with Waters will help our customers in their efforts to bring safe and novel therapeutics to patients, faster.”
 
The workflows in development are based on the pairing of the Waters BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes and will focus on addressing the application needs of GxP laboratories in the following areas: Product variant analysis (e.g. glycosylation, oxidation); bioprocess stability monitoring; and biosimilar glycosylation analysis.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics